Health Care · Pharmaceutical Preparations

REGN Regeneron Pharmaceuticals SEC Filings & Insider Trading Activity 2026

company
CIK 872589120 filings
Nasdaq 100
S&P 500

REGN at a glance

Regeneron Pharmaceuticals (REGN, SEC CIK 872589) filed its latest 10-K annual report on February 4, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Regeneron Pharmaceuticals (REGN) reported revenue of $14.3 billion (up 1.0% from FY2024) and net income of $4.5 billion. Diluted EPS was $41.48.
  • As of September 30, 2026, 49 institutional investment managers tracked by SignalX reported holding Regeneron Pharmaceuticals (REGN) shares worth $34.0 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by MURPHY ANDREW J on November 17, 2026 of 202 shares at $957.53 per share.
  • Regeneron Pharmaceuticals reported 3 positions worth $179.6 million in its 13F-HR for Q3 2026, filed November 5, 2026. Its largest holdings were Parabilis Medicines, Inc. (PBLS) at 74.9%, Intellia Therapeutics, Inc. (NTLA) at 24.9% and Adicet Bio, Inc. (ACET) at 0.2%.
  • In the last 90 days, REGN insiders reported 0 open-market purchases ($0) and 93 open-market sales ($59.2M) on Form 4, a net sale of $59.2M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$14.3B
+1.0% vs prior year
Insiders · 90 days
0 buys · 93 sells
Net −$59.2M
13F holders
49 funds
$34.0B · −2 vs prior quarter
Latest 8-K
Oct 30, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • Lease financing $720M matures March 2027, full payment due unless extended with lender consent
  • Exposure to SOFR-based variable interest rate plus margin tied to debt rating and leverage ratio
  • Liabilities for unrecognized tax benefits $1.578B as of December 31, 2025, with high uncertainty in settlement timing
  • Ongoing R&D and commercialization costs depend on trial outcomes, regulatory approvals, and market potential
  • Contingent payments from collaboration agreements include milestone and royalty payments with unpredictable timing

Management Discussion & Analysis

  • Investment portfolio equity securities decreased to $515.8M (Dec 31, 2025) from $1.307B (Dec 31, 2024)
  • Foreign exchange risk growing due to international sales and operations; foreign currency hedging strategies considered

Business Overview

  • Core business model: Development, manufacturing, and commercialization of innovative biologic drugs and drug-delivery devices with regulatory approval focus
  • New emphasis on expanding internal manufacturing capacity and establishing fill/finish capabilities amid production constraints and pandemic-related impacts
  • Strategic reliance increased on collaborators and contract manufacturers for bulk production and complex device supply chain management
  • Manufacturing capacity limited to facilities in Rensselaer, NY and Limerick, Ireland; investing in expansion and new fill/finish facility undergoing process validation
  • Noteworthy risk: Loss of U.S. market exclusivity for EYLEA as biosimilars launched May 2024, impacting patent protection and revenue outlook

AI summary of the REGN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New U.S. Government Agreements triggered by May 2025 executive order: Most-Favored-Nation pricing and Medicaid product commitments may reduce reimbursement
  • EYLEA HD patent risk heightened by USPTO post-grant review instituted March 2026 for U.S. Patent No. 12,168,036
  • Limerick manufacturing interruption during Q1 and Q2 2026 disrupted bulk production following unanticipated facility repairs
  • EYLEA U.S. net sales declined 41% year over year amid biosimilar competition and other pressures
  • Distributor concentration: two customers represented 77% of total gross product revenue for nine months ended September 30, 2026

Management Discussion & Analysis

  • Revenue $5,115.8M, up $1,361.5M YoY from $3,754.3M
  • Net income $1,948.7M vs $1,460.0M; operating margin 40.0% vs 27.3% YoY
  • Best product line: Dupixent sales $6,540.5M globally; worst: EYLEA sales $658.4M, down 49% YoY
  • Cash $3,659.1M, up $541.0M from December; operating cash flow $3,675.3M, down $132.9M
  • Outlook: 2026 capital expenditures $1.050B to $1.100B; EYLEA headwinds from competition and patient transition to EYLEA HD

AI summary of the REGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $5.1B, up 36%, with non-GAAP EPS $20.07, up 70%, signaling strong operating momentum
  • Sanofi collaboration revenue $2.724B, up 68%, after Development Balance repayment, improving recurring profit participation

Item 2.02: Results of Operations and Financial Condition

  • Regeneron announced financial and operating results for the quarter ended September 30, 2026
  • Results press release furnished as Exhibit 99.1, providing the detailed figures and management commentary period investors should review
Filed Oct 6, 2026Full analysis →

Item 1.01: Entry into a Material Definitive Agreement

  • New collaboration covers four Regeneron-invented long-acting antibodies targeting IL-13, IL-4, IL-4Rα and IL-4xIL-13
  • Sanofi upfront payment: $1.0 billion, plus up to $7.0 billion in development, regulatory and commercial milestones

Item 8.01: Other Events

  • Settlement resolves Regeneron’s lawsuit against Sanofi over Dupixent commercialization information access and audit rights
  • Sixth Amendment remains the governing agreement, with expected payments and new licensed products affecting future economics

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 GAAP and non-GAAP results expected to include approximately $22 million pre-tax acquired IPR&D charge
  • Acquired IPR&D expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.18
Filed Sep 30, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • One-time 10-year PSU awards replace CEO and CSO annual equity through 2036, requiring continued service through December 31, 2035
  • Maximum awards capped at 2,700,000 PSUs for CEO and 2,900,000 for CSO, with mandatory holding through February 2036

Item EX-99.1: Item EX-99.1

  • 10-year PSUs tie executive payouts to pipeline execution, FDA approvals, and New Product Annual Revenues through 2035
  • Revenue hurdles: $10B for 250,000 PSUs, $18B for 900,000, and $30B for 1,800,000

AI summaries of REGN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for REGN

Don't miss the next REGN filing

  • Alerts as it files. A push when REGN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut REGN, by share count.
  • Ask anything. An AI agent that reads every REGN filing and answers with sources.

REGN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
MURPHY ANDREW JSellNov 17, 2026$957.53
MURPHY ANDREW JSellNov 17, 2026$955.48
MURPHY ANDREW JSellNov 17, 2026$956.70
MURPHY ANDREW JSellNov 17, 2026$951.75
MURPHY ANDREW JSellNov 17, 2026$953.69
MURPHY ANDREW JSellNov 17, 2026$954.45
MURPHY ANDREW JSellNov 17, 2026$949.69
MURPHY ANDREW JSellNov 17, 2026$952.75

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$13.1B$14.2B$14.3B
Operating Income$4.0B$4.0B$3.6B
Net Income-$4.4B$4.5B
Op. Margin30.9%28.1%24.9%
Net Margin-31.1%31.4%
Balance Sheet
Total Assets$33.1B$37.8B$40.6B
Equity$26.0B$29.4B$31.3B
ROE-15.0%14.4%
Per Share
EPS$34.77$38.34$41.48
Cash Flow
Operating CF$4.6B$4.4B$5.0B

Source: XBRL data in Regeneron Pharmaceuticals (REGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate REGN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
REGN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202649$34.04B
Q2 202651$28.87B
Q1 202647$35.57B
Q4 202545$34.43B
Q3 202546$27.01B
Q2 202545$23.76B
Q1 202545$25.08B
Q4 202439$21.68B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 367 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

Regeneron Pharmaceuticals top 13F holdings, Q3 2026

Largest reported positions by market value, from the 13F-HR filed Nov 5, 2026

Regeneron Pharmaceuticals 13F holdings for Q3 2026
#CompanyWeightValueSharesvs Q2 2026
1Parabilis Medicines, Inc.PBLS74.90%$134.5M4,166,666Held
2Intellia Therapeutics, Inc.NTLA24.86%$44.7M3,702,995Held
3Adicet Bio, Inc.ACET0.24%$432K60,511Held

Source: Regeneron Pharmaceuticals 13F-HR on SEC EDGAR. Long equity positions only (put and call options excluded); weights are shares of the reported 13F portfolio, not total assets. How 13F filings work

REGN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 18, 2026--
4Nov 6, 2026--
13F-HRNov 5, 2026-
4Nov 5, 2026--
4Nov 5, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 4, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
8-KOct 30, 2026Analysis-
10-QOct 30, 2026Analysis
4Oct 15, 2026--
8-KOct 6, 2026Analysis-
8-KSep 30, 2026Analysis-
4Sep 3, 2026--
4Sep 3, 2026--
4Aug 21, 2026--
4Aug 20, 2026--
4Aug 12, 2026--
4Aug 12, 2026--

Related Health Care companies

All Health Care →

REGN SEC filings: frequently asked questions

Are REGN insiders buying or selling?

In the last 90 days, Regeneron Pharmaceuticals (REGN) officers, directors and 10% owners reported no open-market purchases and 93 open-market sales worth $59.2 million by 9 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold REGN stock?

As of September 30, 2026, the largest Regeneron Pharmaceuticals (REGN) holders among the 13F filers tracked by SignalX were BlackRock ($6.7 billion), Vanguard Capital Management LLC ($4.9 billion), State Street Corp ($3.7 billion), Invesco Ltd ($2.8 billion), Franklin Resources ($2.7 billion). 13F-HR reports are filed up to 45 days after each quarter ends.

What was REGN's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Regeneron Pharmaceuticals (REGN) reported revenue of $14.3 billion (up 1.0% from FY2024) and net income of $4.5 billion. Diluted EPS was $41.48. The figures come from the XBRL data in the 10-K.

What are the main risks in REGN's latest 10-K?

In the 10-K filed February 4, 2026, Regeneron Pharmaceuticals (REGN) flagged: Lease financing $720M matures March 2027, full payment due unless extended with lender consent. Exposure to SOFR-based variable interest rate plus margin tied to debt rating and leverage ratio. (AI summary of the Risk Factors section.)

What did REGN report in its latest 8-K?

Regeneron Pharmaceuticals (REGN) filed an 8-K on October 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $5.1B, up 36%, with non-GAAP EPS $20.07, up 70%, signaling strong operating momentum.

What stocks does Regeneron Pharmaceuticals own?

In its 13F-HR for Q3 2026 (filed November 5, 2026), Regeneron Pharmaceuticals reported 3 positions worth $179.6 million. The largest were Parabilis Medicines, Inc. (PBLS), 74.9%; Intellia Therapeutics, Inc. (NTLA), 24.9%; Adicet Bio, Inc. (ACET), 0.2%. The top 10 positions were 100.0% of the portfolio.

When does Regeneron Pharmaceuticals file 13F reports?

Regeneron Pharmaceuticals's latest 13F-HR was filed November 5, 2026 and covers the quarter ended September 30, 2026. 13F-HR reports are due within 45 days of each quarter-end, so the Q4 2026 report is due by February 14, 2027.

What are the latest REGN SEC filings?

Regeneron Pharmaceuticals (REGN) filed its latest 10-K annual report on February 4, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on November 18, 2026.

What is REGN's SEC CIK number?

Regeneron Pharmaceuticals (REGN)'s SEC Central Index Key (CIK) is 872589. EDGAR lists every REGN filing under that number.

Ask anything about REGN

The research agent reads REGN's filings, financials, insider trades and 13F holders, then answers with sources.